Exchange: NASDAQ·Updated 07:45 PM EDT
News
all
press releases
InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know
InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
More News
InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates
InspireMD (NSPR) delivered earnings and revenue surprises of +15.00% and +7.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices (MASS) delivered earnings and revenue surprises of +21.43% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.
Zacks
InspireMD NSPR Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
InspireMD (NSPR) delivered earnings and revenue surprises of +15.79% and +25.85%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance
The trial will test the safety and effectiveness of SwitchGuard when used with the company’s CGuard Prime carotid stent during transcarotid artery revascularization or TCAR procedures.
Stocktwits
InspireMD (NYSE:NSPR) Stock Price Up 3.5% - What's Next?
InspireMD (NYSE:NSPR) Stock Price Up 3.5% - Here's What Happened...
MarketBeat

Advertisement|Remove ads.